"Tesamorelin before and after" is searched mostly by people who are not in the population it was approved for. The drug's results come from a narrow, well-measured place: adults with HIV whose abdominal fat had accumulated on antiretroviral treatment, scanned by CT at the fourth and fifth lumbar vertebrae. This page sets out those results from the label itself, what two later trials added, and what was never tested.
Doses are on our tesamorelin dosage page, and adverse effects — including the IGF-1 rises and antibodies the label reports — on our tesamorelin side effects page. Nothing here is a recommendation; use outside the label is a decision for a clinician.
What the approval rests on
The current EGRIFTA WR label (revised 3/2025, accessdata.fda.gov, read 6 October 2026) reports two multicentre, randomised, double-blind, placebo-controlled studies:
- Who: adults 18 to 65 with HIV on stable antiretroviral treatment, waist ≥95 cm and waist-to-hip ratio ≥0.94 for men (≥94 cm and ≥0.88 for women), fasting glucose under 150 mg/dL. People with diabetes on treatment were excluded.
- What: 2 mg tesamorelin or placebo under the skin daily, randomised 2:1, for 26 weeks; then tesamorelin patients were re-randomised to continue or switch to placebo for 26 more.
- The measure: percentage change in visceral adipose tissue (VAT) on a CT slice at L4–L5. Not weight, not a tape measure, not a photograph.
The results at 26 weeks
From the label's Tables 2 and 3 (intent-to-treat, last observation carried forward):
| Study 1 — tesamorelin (n=273) | Study 1 — placebo (n=137) | Study 2 — tesamorelin (n=270) | Study 2 — placebo (n=126) | |
|---|---|---|---|---|
| Visceral fat at start (cm²) | 178 | 171 | 186 | 195 |
| Change in visceral fat (cm²) | −27 | +4 | −21 | −0 |
| Change in visceral fat (%) | −18% | +2% | −14% | −2% |
| Difference vs placebo | −20% (95% CI −24 to −15) | −12% (95% CI −16 to −7) | ||
| Change in IGF-1 (ng/mL) | +107 | −15 | +108 | +3 |
| Change in weight (kg) | −0.4 | 0.0 | +0.5 | +0.3 |
| Change in waist (cm) | −3 | −1 | −2 | −1 |
The label adds that trunk fat fell by 1.0 and 0.8 kg (placebo: +0.4 and +0.2 kg) and lean body mass rose by 1.3 and 1.2 kg (placebo: −0.2 and −0.03 kg). Fat went down and lean mass went up by similar amounts, which is why weight did not move. The label puts it directly: tesamorelin "is not indicated for weight loss management as it has a weight neutral effect."
The first published report of the phase 3 programme (Falutz et al., JAIDS 2010, PMID 20101189) adds the point most "belly fat" pages leave out: there was no change in limb or abdominal subcutaneous fat — the fat that can be pinched. What fell was the fat inside the abdomen.
When it stops
The extension phase tested what most clinic pages do not mention. Among patients who had taken tesamorelin for 26 weeks:
| Weeks 26–52 | Study 1 continued (n=154) | Study 1 switched to placebo (n=50) | Study 2 continued (n=92) | Study 2 switched to placebo (n=85) |
|---|---|---|---|---|
| Change in visceral fat (cm²) | +3 | +25 | −11 | +24 |
| Change (%) | 0% | +22% | −5% | +16% |
Six months after stopping, much of the visceral fat lost in the first six months had returned. Falutz 2010 describes the initial improvements as "rapidly lost" in those switched to placebo. How this compares with the other approved peptides that tested withdrawal is on our how long do peptides take to work page.
Not everyone responded
The trials defined a responder in advance as someone whose visceral fat fell by at least 8%. In a post-hoc analysis of the 402 people first randomised to tesamorelin in the per-protocol population (Stanley et al., Clin Infect Dis 2012, PMID 22495074), responders had larger falls in triglycerides and kept fasting glucose and HbA1c steadier over 52 weeks than non-responders. The label's limitation of use reflects the same split: "Consider risk/benefit of continuation of treatment in patients who have not had a reduction in visceral adipose tissue."
What later trials added
| Trial | Who | What was given | Result |
|---|---|---|---|
| Stanley et al., Lancet HIV 2019 | 61 adults with HIV and liver fat ≥5% | 2 mg daily vs placebo, 12 months | Liver fat fraction −4.1 percentage points vs placebo (95% CI −7.6 to −0.7), a 37% relative fall; 35% vs 4% ended below 5%; glucose and HbA1c no different between groups |
| Baker et al., Arch Neurol 2012 | 152 adults 55–87 without HIV, 66 with mild cognitive impairment | 1 mg nightly vs placebo, 20 weeks | Favourable effect on a cognitive composite (P = .03), mainly executive function; IGF-1 +117%; percent body fat −7.4%; adverse events in 68% vs 36% on placebo |
The Baker trial is the only randomised tesamorelin trial found in people without HIV that reported a body-fat measure. It was a cognition trial, it used half the labelled dose, and body fat was a secondary measurement by DEXA. It shows the drug changes body composition outside HIV; it does not establish a fat-loss result for anyone.
What a "before and after" can and cannot show
The trials measured visceral fat at week 13 and week 26 by CT, and the label's primary result is at week 26. A fall of around 20 to 30 cm² in the fat inside the abdomen, on a single CT slice, is real and measurable on a scanner. Whether it shows in a mirror or a photograph was never studied: the fat that can be seen and pinched, under the skin, did not change in the phase 3 report, and no trial used a photograph as an outcome. The same point applies to sermorelin's "before and after".
What is not established
- Any fat-loss effect in people without HIV, in a trial designed to measure it.
- Any effect at compounded or research-market doses or schedules, or of products that are not EGRIFTA.
- Long-term cardiovascular safety, which the label states "has not been established".
- Whether visceral fat reductions persist without continued treatment; the trials found they did not.
Tesamorelin's place among the approved peptides is on our FDA-approved peptides census; its comparison with ipamorelin is on our tesamorelin vs ipamorelin page. Peptide Lexicon's tesamorelin entry explains the molecule.
Sources and dates
- EGRIFTA WR (tesamorelin) prescribing information, revised 3/2025, Tables 2–4 and section 1, accessdata.fda.gov. Read 2026-10-06. Kind of source: approved label (tier 1).
- Falutz J et al. Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation. J Acquir Immune Defic Syndr 2010;53(3):311–22. PMID 20101189. Read 2026-10-06.
- Stanley TL et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis 2012;54(11):1642–51. PMID 22495074. Read 2026-10-06.
- Stanley TL et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV 2019;6(12):e821–30. PMID 31611038. Read 2026-10-06.
- Baker LD et al. Effects of GHRH on cognitive function in adults with mild cognitive impairment and healthy older adults. Arch Neurol 2012;69(11):1420–9. PMID 22869065. Read 2026-10-06.
- Drugs@FDA via openFDA, EGRIFTA application 022505, read 2026-10-06.